This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
PBYI Surges 30% in 3 Months: How Should You Play the Stock?
by Zacks Equity Research
Puma Biotechnology shares rise nearly 30% in three months on rising Nerlynx sales, with key data on pipeline drug alisertib due later this year.
RHHBYNegative Net Change PBYIPositive Net Change ANIPPositive Net Change CRMDNegative Net Change
biotechs
CorMedix Rallies 60% YTD: Is This an Indication to Buy the Stock?
by Ahan Chakraborty
CRMD stock surges nearly 60% YTD as DefenCath drives strong sales, boosted by a $300M Melinta acquisition deal and raised revenue outlook.
PFEPositive Net Change AMPHNegative Net Change CRMDNegative Net Change
biotechnology biotechs medical pharmaceuticals
REGN Loses 21.1% Year to Date: Buy, Sell or Hold the Sock?
by Zacks Equity Research
Regeneron shares slump as Eylea struggles, but Dupixent gains and a strengthening oncology pipeline offer growth potential.
REGNPositive Net Change SNYNegative Net Change RHHBYNegative Net Change BAYRYNegative Net Change
biotechnology biotechs medical pharmaceuticals
Zoetis Gains CVMP Backing for Portela, Eyes EU Approval in Cat OA Pain
by Zacks Equity Research
ZTS secures CVMP's positive opinion recommending the approval of Portela, a long-acting OA pain therapy for cats, with final decision expected in late 2025.
ZTSNegative Net Change CRMDNegative Net Change KNSANegative Net Change PHARNegative Net Change
biotechnology biotechs medical pharmaceuticals
COVID-19 Vaccine Stocks Fall on Reports Linking Shots to Child Deaths
by Sundeep Ganoria
MRNA, BNTX, PFE and NVAX stocks fall as health officials reportedly plan to link COVID-19 vaccines to child deaths ahead of a key CDC meeting.
PFEPositive Net Change MRNAPositive Net Change NVAXPositive Net Change BNTXPositive Net Change
biotechs medical pharmaceuticals vaccines
RAPP Stock Soars 62% in a Week on Meeting Phase II Epilepsy Study Goal
by Zacks Equity Research
Rapport Therapeutics stock jumps 62% in a week as mid-stage study of RAP-219 meets goals in drug-resistant epilepsy patients.
CRMDNegative Net Change KNSANegative Net Change PHARNegative Net Change RAPPPositive Net Change
biotechnology biotechs medical pharmaceuticals
OLMA Stock Soars 47% in September So Far on Second PFE Deal
by Zacks Equity Research
Olema Pharmaceuticals surges 47% in September after striking a second collaboration with Pfizer for its lead breast cancer product candidate, palazestrant.
AZNNegative Net Change NVSNegative Net Change PFEPositive Net Change OLMAPositive Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
AbbVie Settles Rinvoq Patent Dispute: What It Means for the Stock
by Sundeep Ganoria
ABBV secures Rinvoq's market lead until 2037, boosting shares as strong sales and new indications fuel long-term growth prospects.
JNJNegative Net Change LLYNegative Net Change ABBVNegative Net Change
biotechs medical pharmaceuticals
BMY-BioNTech Partnership: A Potential Catalyst for Long-Term Gains?
by Ekta Bagri
Bristol Myers and BioNTech report strong mid-stage lung cancer trial data for pumitamig, showing high response rates and manageable safety.
BMYPositive Net Change PFEPositive Net Change MRKNegative Net Change BNTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
Is BDTX's Cash balance Enough to Successfully Develop Its NSCLC Drug?
by Ekta Bagri
Black Diamond sharpens focus on silevertinib after outlicensing BDTX-4933, cutting costs, and securing cash runway into late 2027.
AZNNegative Net Change JNJNegative Net Change BDTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
SNY's Gene Therapy Candidate for Eye Disease Gets FDA Fast Track Tag
by Zacks Equity Research
Sanofi's gene therapy SAR402663 for wet AMD earns FDA fast track status, aiming to speed up development and reduce treatment burden.
SNYNegative Net Change ABBVNegative Net Change RGNXNegative Net Change FDMTNegative Net Change
biotechs medical pharmaceuticals
TVTX Stock Soars as FDA Waives Advisory Committee for Filspari sNDA
by Zacks Equity Research
Travere Therapeutics stock jumps after the FDA drops advisory meeting for Filspari's FSGS filing, with approval decision due in January 2026.
CRMDNegative Net Change KNSANegative Net Change TVTXNegative Net Change PHARNegative Net Change
biotechnology biotechs medical pharmaceuticals
Where Does VKTX Stock Stand After the Obesity Pill Setback?
by Sundeep Ganoria
Viking Therapeutics faces pressure after mixed oral obesity pill trial results, raising safety concerns but still meeting key study goals.
NVOPositive Net Change LLYNegative Net Change AMGNNegative Net Change VKTXNegative Net Change
biotechs medical pharmaceuticals
Prothena Down 40% Year to Date: What Lies Ahead for the Stock?
by Zacks Equity Research
Prothena stock tumbles 40% year to date due to pipeline setbacks, though its partnered programs with Roche and Novo Nordisk still show potential.
RHHBYNegative Net Change BMYPositive Net Change NVOPositive Net Change PRTANegative Net Change
biotechnology biotechs medical pharmaceuticals
Bristol Myers Loses 19.2% in Six Months: Buy, Sell or Hold?
by Ekta Bagri
Bristol Myers struggles with falling shares and legacy drug headwinds, but growth drugs and new approvals help steady revenues.
BMYPositive Net Change PFEPositive Net Change MRKNegative Net Change BNTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
NVS to Acquire TRML, Add Phase III Cardiovascular Drug to Pipeline
by Zacks Equity Research
Novartis is set to acquire Tourmaline Bio for $1.4B, adding late-stage anti-IL-6 candidate pacibekitug to its cardiovascular pipeline.
NVSNegative Net Change NVOPositive Net Change ARWRNegative Net Change TRMLPositive Net Change
biotechnology biotechs medical pharmaceuticals
Is NVO's Major Restructuring Plan an Indication to Sell the Stock?
by Ahan Chakraborty
Novo Nordisk's sweeping restructuring plan cuts 9,000 jobs, targets DKK 8 billion in savings, and shifts focus to obesity and diabetes R&D.
NVOPositive Net Change LLYNegative Net Change AMGNNegative Net Change VKTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
SMMT Stock Plummets 25% on Regional Data Differences in NSCLC Study
by Zacks Equity Research
Summit Therapeutics plunges 25% after its HARMONi study shows sharp regional differences in lung cancer trial outcomes.
BMYPositive Net Change MRKNegative Net Change SMMTNo Net Change BNTXPositive Net Change
biotechs medical pharmaceuticals
Will LLY's Oncology Portfolio Provide Key Diversification Benefits?
by Ahan Chakraborty
Eli Lilly's oncology portfolio, led by Verzenio and Jaypirca, is adding diversification to its cardiometabolic-driven growth story.
AZNNegative Net Change PFEPositive Net Change MRKNegative Net Change LLYNegative Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
RARE Reports Positive Long-Term Data From Metabolic Disorder Study
by Zacks Equity Research
Ultragenyx posts 96-week data showing DTX401 sharply cuts cornstarch needs and improves life quality in GSDIa patients.
RARENegative Net Change CRMDNegative Net Change KNSANegative Net Change PHARNegative Net Change
biotechnology biotechs gene-therapy medical pharmaceuticals
ALVO Stock Trades Near 52-Week Low: Should You Buy, Hold or Sell?
by Sundeep Ganoria
Alvotech trades near a 52-week low after a 38% drop in 2025, but soaring revenues and new biosimilar approvals highlight its growth path.
RDYNegative Net Change TEVANegative Net Change ALVOPositive Net Change
biotechs medical
Can ALNY's Key Partnerships With Pharma Giants Drive Long-Term Growth?
by Ahan Chakraborty
Alnylam's strong drug sales and advancing partnerships with Regeneron and Roche highlight key growth drivers in the quarters ahead.
ALNYNegative Net Change PFEPositive Net Change BBIOPositive Net Change
biotechnology biotechs medical pharmaceuticals
Leveraged ETF Areas of Last Week That Are Up At least 15%
by Sanghamitra Saha
Tech rally, weak jobs data and Fed rate cut bets were highlights of last week. Winning leveraged ETFs were GDXU, SOUX, AVGG, GGLL and LABU.
AVGOPositive Net Change GOOGLPositive Net Change LABUNegative Net Change JNUGPositive Net Change AVGGPositive Net Change GDXUPositive Net Change GGLLPositive Net Change GOOXPositive Net Change AVGXPositive Net Change SOUXNegative Net Change
biotechs etfs
BDTX Stock Surges 51.1% in Six Months: Is There More Room for Growth?
by Ekta Bagri
Black Diamond shines with a 51.1% stock surge, fueled by silevertinib's progress and pipeline momentum in oncology.
AZNNegative Net Change JNJNegative Net Change BDTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
RHHBY Posts Positive Data on Vabysmo in nAMD at Euretina Congress
by Zacks Equity Research
Roche posts strong new data for Vabysmo in eye disease, with extended dosing and vision gains driving growth.
REGNPositive Net Change RHHBYNegative Net Change BAYRYNegative Net Change
biotechnology biotechs medical pharmaceuticals